This program is supported by an independent education grant from MSD. This online education program has been designed solely for healthcare professionals in the US. The content is not intended for healthcare professionals in any other country.

Credits: AMA PRA Category 1 Credits™ (0.50.00 hours)

Type of activity: Enduring material (Podcast)

Launch date: 9 July 2026

Expiration date: 29 November 2027

Estimated time to complete this activity: 30 minutes

Join leading bladder cancer expert Dr. Matthew Galsky for this accredited CME expert podcast episode, "From Signal to Action: Understanding Biomarkers in Real-World Bladder Cancer Care". This focused, 30-minute conversation explores the real-world interpretation of pathology, imaging, and clinical risk features that inform critical treatment planning across diverse healthcare environments.

Through concise, practical discussion, the session outlines how clinicians can utilize diagnostic signals to determine when to escalate care, when a referral is essential, and how to adapt decisions when information is delayed or resources are limited. By unpacking critical diagnostic and prognostic markers—including tumor grade, stage, variant histology, LVI, completeness of TURBT, imaging red flags, and nodal risk—the faculty will demonstrate how to translate complex clinical signals into clear, actionable next steps. Participants will gain practical heuristics to safely manage patients locally versus prioritizing a timely referral, ensuring consistent, guideline-aligned care across community, rural, and hospital settings.

This is podcast has three segments:

• Segment 1: The Markers That Define Risk
• Segment 2: When Markers Trigger Escalation or Referral
• Segment 3: Applying Diagnostic Insight Across Different Care Environments

Who Should Attend?

This program is designed for healthcare professionals in the US, directly involved in diagnosing, staging, and managing bladder cancer and making treatment-planning decisions across community, rural, and hospital settings, including:

• Urologists (generalists, community urologists, and academic specialists)
• Medical Oncologists involved in bladder cancer management
• Advanced Practice Providers (nurse practitioners, physician associates) in urology and oncology
• Urology Nurses and Oncology Nurses
• Primary Care Clinicians in community or rural settings who participate in referral decisions
• Allied Health Professionals supporting bladder cancer coordination and follow-up

Faculty

Matthew Galsky, MD is an oncologist with expertise in treating genitourinary cancers such as bladder cancer, prostate cancer, kidney cancer, and testicular cancer. His clinical and translational research has helped lead to paradigm-shifting FDA approvals of new treatments and perioperative regimens for bladder cancer. Dr. Galsky currently leads clinical trials investigating novel immunotherapeutic approaches and combination strategies. These immunotherapy options focus on checkpoint inhibitors that release the brakes on a patient’s immune system, helping it mount a stronger, more effective response against cancer.

Continuing Education Information

Commercial support: This activity received monetary support through an independent education grant from MSD.

This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.

Faculty Disclosure Statement / Conflict of Interest

Matthew Galsy, MD has disclosed financial interests or relationships with the following ineligible companies that have ended within the past 24 months: Consulting for Abbvie Inc., BMS, Janssen, Merck, Pfizer. Dr Galsky does not intend to reference unlabeled or unapproved uses of drugs or products.

AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.

Mitigation of Relevant Financial Relationships

AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. Relevant financial relationships were mitigated by the peer review of content by non-conflicted reviewers prior to the commencement of the program.

Activity Accreditation for Health Professions

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses & Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

System Requirements

Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program.

Unapproved and/or off-label use disclosure

AffinityCE/MedAll requires CE faculty to disclose to the participants:

• When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
• Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

CME Inquiries

For all CME policy-related inquiries, please contact us at ce@affinityced.com.

Participation Costs

There is no cost to participate in this program.

To Earn CME Credit:

1. Review the program materials

2. Click the green button on the right to "Claim CME credit"

3. Complete the Post-Test; this test features real-time learning. You will receive immediate feedback and rationales explaining the correct answers as you go.

4. Once you have successfully passed the test and completed the required CME evaluation, your certificate will be available for download and emailed to you.

Disclaimer

This activity is intended for educational purposes only and does not establish a standard of care or replace clinical judgment. Any therapeutic or diagnostic strategies discussed must be evaluated in the context of each patient’s clinical circumstances, risks, and current evidence.

Learners should consult authoritative clinical guidelines and approved product information when considering treatment decisions.

All materials are used with permission. The views expressed are those of the faculty and do not necessarily reflect those of the accredited providers, MedAll, or any supporters.

Content is accurate as of the date of release.